Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which...
25 insider purchases on record · latest filing 2026-01-12.
Insiders have also filed 195 sale transactions at AKTS.